Delveinsight

JULY 21, 2021

The body produces antibodies to fight infections, but in the case of Autoimmune diseases, the antibodies start attacking the body’s cells, tissues, and organs. However, some of the key pharma companies at the global level have shifted their focus towards these diverse diseases.

Pharma Companies 94

Pharma Companies Marketing Development Insulin 94

Pharmaceutical Technology

SEPTEMBER 2, 2022

lenalidomide) + a steroid ± an anti-CD38 antibody. Since the frontline treatment setting is dominated by these regimens, pharma companies have focused on the development of new drugs in the relapsed/refractory (R/R) setting. Should CAR-T cells, or antibodies be used first?

Antibody 147

Antibody Sales FDA Approval Production 147

Fierce Pharma

JULY 25, 2024

Large pharma companies are still looking for deals in China. AstraZeneca and Daiichi Sankyo's antibody-drug conjugate star Enhertu experienced a slow quarter. Large pharma companies are still looking for deals in China. AstraZeneca and Daiichi Sankyo's ADC star Enhertu slowed down.

Pharma Companies 76

Pharma Companies Antibody Drugs 76

BioSpace

SEPTEMBER 17, 2023

The deal is an expansion of an existing production agreement between the companies and just one of several deals with large pharma companies that the Korean biotech has scooped up this year.

Antibody 68

Antibody Manufacturing Pharma Companies Production 68

Fierce Pharma

AUGUST 20, 2024

After picking up the European rights to Eli Lilly’s Emgality and Rayvow late last year, women’s health outfit Organon is upping its migraine accord with the Big Pharma company.

Pharma Companies 78

Pharma Companies Marketing Antibody 78

XTalks

MAY 29, 2024

The top ten pharma companies in 2023 by revenue accounted for about 35 percent of the market value, with total earnings of $559.5 The top big pharma players have remained relatively consistent in their market positions over the past several years. Here is a look at the top ten pharma companies in 2024 based on 2023 revenue.

Pharma Companies 52

Pharma Companies Sales FDA Approval Vaccination 52

Pharmaceutical Technology

APRIL 17, 2023

Telix has announced the successful preclinical development of radiolabelled olaratumab, an antibody licensed by Eli Lilly and Company. If the Australian pharma company can demonstrate a renewed potential for the drug, Lilly could receive up to $255m in commercial and regulatory milestone payments.

Development 130

Development Antibody Pharma Companies Licensing 130

pharmaphorum

NOVEMBER 30, 2020

Neutralising antibodies (NAbs) present a unique challenge to researchers looking to treat patients with AAV treatment. Cure Rare Disease’s Rich Horgan discusses the importance of preclinical NAbs screening and helping rare disease patients better understand their eligibility for gene therapies.

Gene Therapy 105

Gene Therapy Gene Antibody Clinical Trials 105

pharmaphorum

DECEMBER 8, 2020

AbCellera Biologics has been in the spotlight since coming up with Eli Lilly’s COVID-19 antibody drug bamlanivimab, and looks set to capitalise on that exposure with a sizeable initial public offering. The drug is also being tested in other trials, including a phase 3 study looking at its role in prevention of SARS-CoV-2 infection.

Drugs 111

Drugs Antibody FDA Approval Pharma Companies 111

pharmaphorum

JULY 12, 2021

A diagnostic test to detect long COVID could be available within six to 12 months, following the discovery that patients with the chronic condition have distinctive antibodies in their blood. . Read more in today's Observer [link]. — APPG on Coronavirus (@AppgCoronavirus) July 11, 2021.

Antibody 105

Antibody Pharma Companies Research Vaccination 105

Fierce Pharma

AUGUST 8, 2024

Three large pharma companies are locked in a high-stakes antibody-drug conjugate race. Three large pharma companies are locked in a high-stakes antibody-drug conjugate race. Merck and Daiichi Sankyo teamed up on a DLL3 T-cell engager. Merck and Daiichi Sankyo teamed up on a DLL3 T-cell engager. billion.

Pharma Companies 52

Pharma Companies Antibody Drugs 52

Fierce Pharma

AUGUST 15, 2024

The TROP2 antibody-drug conjugate race has heated up among three Big Pharma companies: Gi | In this week’s episode of “The Top Line,” Fierce executive editor Eric Sagonowsky chats with Angus Liu about his feature story on the three TROP2 front-runners.

Pharma Companies 59

Pharma Companies Antibody Drugs 59

pharmaphorum

DECEMBER 21, 2021

Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate in an existing partner, Chinese biotech BeiGene. Pharma companies are looking at whether blocking TIGIT as well as PD-1/PD-L1 can improve the efficacy of cancer immunotherapy.

Drugs 98

Drugs Antibody Pharma Companies Development 98

BioPharma Reporter

SEPTEMBER 19, 2023

The big pharma company Bristol Myers Squibb (BMS) has recruited contract manufacturing and development organization (CDMO) Samsung Biologics to manufacture a commercial antibody cancer treatment until 2030.

Manufacturing 59

Manufacturing Contract Manufacturing Pharma Companies Antibody 59

pharmaphorum

APRIL 21, 2022

One of the leading companies in the bid to bring a new class of alpha-synuclein targeting drugs to market for Parkinson’s disease – AbbVie – is ducking out of the challenge. AZ/Takeda are meanwhile running phase 2 trials of their MEDI 1342 antibody candidate. Interest in the target has also prompted a flurry of licensing deals.

Antibody 97

Antibody Protein Gene Therapy Pharma Companies 97

pharmaphorum

AUGUST 18, 2020

This is a question that a consortium of European pharma companies hopes to answer as it aims to rapidly develop new therapies to combat the pandemic. The consortium aims to rapidly develop drugs to fight SARS-CoV-2 and find virus neutralising antibodies. But also included in the 77.7

Protein 121

Protein Pharma Companies RNA Drugs 121

XTalks

JANUARY 20, 2025

This strategic move transformed Actavis into one of the largest pharma companies globally, with a strong presence across branded, generic and over-the-counter (OTC) medicines. Actavis Acquisition of Allergan Deal value : $70.5

Marketing 104

Marketing Botox Life Science Pharma Companies 104

BioPharma Reporter

NOVEMBER 6, 2023

The big pharma company Bristol Myers Squibb (BMS) committed up to $180 million for a phase 1-ready antibody-drug conjugate (ADC) for the treatment of blood cancer from the U.S.-South South Korean biotech company Orum Therapeutics.

Protein 52

Protein Pharma Companies Antibody Drugs 52

pharmaphorum

JUNE 1, 2022

Astellas has become the latest big pharma company to sink some money into immuno-oncology start-up GO Therapeutics, forging an alliance to develop antibodies targeting two glycoprotein targets. The Japanese drugmaker is paying $20.5

Gene Therapy 98

Gene Therapy Clinical Development Antibody Gene 98

Pharmaceutical Technology

SEPTEMBER 8, 2022

The increasing number of approvals of biologics over the years has increased the volume of contracts for innovator APIs and biologic-dose outsourcing.

Gene 100

Gene Marketing Vaccination Vaccine 100

pharmaphorum

APRIL 19, 2021

The French pharma just signed a deal with C4XD to develop drugs that could lead to oral medicines for inflammatory diseases such as psoriasis, as big pharma looks for more patient-friendly alternatives to therapies based on injections of antibody-based drugs. It spotlighted the UK as a place to do clinical development.

Vaccination 98

Vaccination Vaccine Life Science Antibody 98

The Pharma Data

DECEMBER 11, 2020

The test has been designed to quantitatively measure of immunoglobulin G (IgG) antibodies to aid clinicians in identifying patients with an immune Covid-19 response pre- and post-vaccination. As we follow individuals over the course of a year, we are repeatedly testing them for both virus and antibodies.”.

Antibody 52

Antibody Vaccination Vaccine Containment 52

pharmaphorum

JUNE 4, 2021

At the moment, Xofigo is the only approved TAT on the market, but Bayer is also developing a pipeline of other candidates based on thorium-227 linked to antibodies or small-molecule drugs. Its other clinical stage TAT (BAY 2287411) also uses an antibody and targets mesothelin, an antigen found on the surface of tumour cells.

Antibody 81

Antibody Licensing Licensing Protein 81

pharmaphorum

AUGUST 21, 2020

This is a question that a consortium of European pharma companies hopes to answer as it aims to rapidly develop new therapies to combat the pandemic. Could AI prevent future pandemics by developing an armoury of drugs that work against all coronaviruses?

Vaccination 105

Vaccination Vaccine Regulation Manufacturing 105

pharmaphorum

APRIL 7, 2021

While the Darzalex revenues are due to fall this year because of Janssen’s interpretation of the agreement between the two companies, there are also other revenue streams. With other drugs in the pipeline too, van de Winkel said the company aims to continue to break new ground with next-generation antibody-based therapies.

Antibody 91

Antibody Life Science Development Drugs 91

XTalks

FEBRUARY 19, 2021

In the latest round of Amgen’s (NASDAQ: AMGN ) ongoing patent battle against Regeneron (NASDAQ: REGN ) and Sanofi over LDL-lowering PCSK9 (proprotein convertase subtilisin/kexin type 9) antibodies, the latter came out with a win last week. However, other companies, including Bristol Myers Squibb and Merck & Co.,

Antibody 85

Antibody Sales Trials Marketing 85

pharmaphorum

MARCH 15, 2022

A group of pharma companies and academic groups have joined forces with the Digital Medicine Society (DiMe) to develop standardised, digital clinical measures that can be used in the development of therapies for Alzheimer’s disease and related dementias.

Development 111

Development Pharma Companies Clinical Trials Clinical Trials 111

pharmaphorum

AUGUST 2, 2022

Antibody-drug conjugates are coming back to the fore, with talks of multi-billion dollar buyouts and a rapidly growing number of approvals. Antibody-drug conjugates (ADCs) are a class of biologic drugs designed for targeted treatment of cancer.

Marketing 98

Marketing Antibody Drugs Clinical Trials 98

pharmaphorum

SEPTEMBER 18, 2020

But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharma companies in the world: AstraZeneca.

Pharma Companies 116

Pharma Companies Sales Vaccination Vaccine 116

pharmaphorum

FEBRUARY 9, 2022

The promise of this approach means that there is now a growing pipeline of potential cancer vaccines emerging from within the portfolios of larger pharma companies and biotechs. While therapeutic cancer vaccines are able to help the body identify particular proteins expressed by cancer cells and then to instigate an immune response.

Vaccination 134

Vaccination Vaccine Clinical Trials Clinical Trials 134

Delveinsight

AUGUST 2, 2020

Helsinn Group , a Swiss pharma player, is evaluating Anamorelin, an orally active selective ghrelin receptor agonist against Cancer cachexia, The company is conducting Phase III trial to test the efficacy and safety of anamorelin for the treatment of weight loss and anorexia in patients with advanced NSCLC with cachexia.

Marketing 94

Marketing Pharma Companies Development Hormones 94

pharmaphorum

JUNE 16, 2021

California biotech Ambrx Biopharma is hoping to raise $126 million from a listing on the New York Stock Exchange (NYSE) that will be used in part to fund clinical development of ARX-788, its HER2-targeting antibody drug conjugate (ADC).

Antibody 59

Antibody Sales Drugs Trials 59

pharmaphorum

MAY 12, 2021

Lilly’s head of new therapeutic modalities, Andrew Adams, said that saRNAs are “a promising new technology, which will expand the breadth of Lilly’s RNA therapeutics platform and the targets we can pursue” The US pharma company has been building a presence in RNA medicines via a series of partnerships, including a $1.2

RNA 76

RNA Protein Drugs Pharma Companies 76

pharmaphorum

SEPTEMBER 20, 2022

Vaccines have transitioned from being a largely unloved area of the industry, with multiple big pharma companies divesting their vaccine divisions , to the biggest revenue drivers seen in recent years. Serum neutralising antibody increases were noted to be particularly high in subjects who had previously received an mRNA vaccine.

Vaccination 98

Vaccination Vaccine Immune Response Antibody 98

pharmaphorum

FEBRUARY 14, 2022

In figures, this was represented by 71% of late-stage pipeline revenue being the result of the companies partnering to develop an asset. Due to the increase in funding, more biotechs and smaller scale pharma companies are able to progress assets further into clinical trials.

Production 98

Production Clinical Trials Clinical Trials Sales 98

pharmaphorum

FEBRUARY 15, 2022

ImmunoGenAlmost four years after backing out of an antibody-drug conjugate (ADC) alliance with ImmunoGen, Eli Lilly has come back to the table with a new, wide-ranging deal worth up to $1.7 Lilly is thought to be the first pharma company to sign up to use the new camptothecin payload platform.

Antibody 52

Antibody Licensing Licensing Drugs 52

XTalks

OCTOBER 22, 2020

In this sense, pharmaceutical companies have developed different strategies to produce a wide variety of advanced therapy medicinal products (ATMP) and biological products, such as monoclonal antibodies, recombinant proteins, gene therapy viral vectors, CAR-T cells and oncolytic viruses, in order to deliver new medical needs in our society.

Manufacturing 98

Manufacturing Development Production Gene Therapy 98